Skip to content

Study · Measured the body's own peptide · 2002

4 results

Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells.

Kobayashi T, Okada F, Fujii N, Tomita N, Ito S, Tazawa H, Aoyama T, Choi SK, Shibata T, Fujita H, Hosokawa M

The American journal of pathology1 Mar 2002Cited by 97 (Europe PMC)

PMID11891186 (opens in a new tab)DOI10.1016/s0002-9440(10)64910-3 (opens in a new tab)PepBankPUB-11891186
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In syngeneic C57BL/6 mice, up-regulation of thymosin-beta4 in QR-32 cells by sense cDNA transfection led to tumor development and numerous lung metastases.

    In plain wordsIn mice, raising thymosin-beta4 expression in mouse tumor cells made the cells form tumors and lung metastases.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTumor formation and lung metastasis after Tb4 up-regulation
    Study

    mousen: not reported in source

    QR-32 cells with sense Tb4 cDNA in syngeneic C57BL/6 mice
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Up-regulation of thymosin-beta4 in QR-32 cells (32-S) transfected with sense thymosin-beta4 cDNA converted the cells to develop tumors and formed numerous lung metastases in syngeneic C57BL/6 mice.
    1 context sentence
    Summary · context
    We identified a thymosin-beta4 gene overexpression in malignant mouse fibrosarcoma cells (QRsP-30) that were derived from clonal weakly tumorigenic and nonmetastatic QR-32 cells by using a differential display method.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In mice, antisense thymosin-beta4 cDNA reduced thymosin-beta4 expression in QRsP-30 cells, and the cells significantly lost tumor formation and metastases to distant organs.

    In plain wordsIn mice, lowering thymosin-beta4 expression in malignant mouse cells greatly reduced tumor formation and spread.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTumor formation and metastasis after Tb4 knockdown
    Study

    mousen: not reported in source

    QRsP-30 cells with antisense Tb4 cDNA in syngeneic C57BL/6 mice
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In contrast, antisense thymosin-beta4 cDNA-transfected QRsP-30 (30-AS) cells reduced thymosin-beta4 expression, and significantly lost tumor formation and metastases to distant organs.
    1 context sentence
    Summary · context
    We identified a thymosin-beta4 gene overexpression in malignant mouse fibrosarcoma cells (QRsP-30) that were derived from clonal weakly tumorigenic and nonmetastatic QR-32 cells by using a differential display method.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03LabEndogenous levelIn vitro (cells)Mechanism

    In six malignant mouse fibrosarcoma cell lines derived from QR-32 cells, thymosin-beta4 mRNA was high, and expression correlated with tumorigenicity and metastatic potential.

    In plain wordsIn mouse cancer cells, high natural thymosin-beta4 levels were linked to tumor-forming and spreading ability.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTb4 mRNA in malignant fibrosarcoma lines
    Study

    mousen = 6

    Mouse fibrosarcoma cell lines (QR-32 and derived malignant lines)
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    All of the six malignant fibrosarcoma cell lines that have been independently converted from QR-32 cells expressed high levels of thymosin-beta4 mRNA and its expression in tumor cells was correlated with tumorigenicity and metastatic potential.
    1 context sentence
    Summary · context
    We identified a thymosin-beta4 gene overexpression in malignant mouse fibrosarcoma cells (QRsP-30) that were derived from clonal weakly tumorigenic and nonmetastatic QR-32 cells by using a differential display method.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  4. 04LabEndogenous levelIn vitro (cells)Mechanism

    In mouse fibrosarcoma cells, tumor cell motility, cell shape and F-actin organization were regulated in proportion to the level of thymosin-beta4 expression.

    In plain wordsIn mouse cancer cells, movement, shape and actin organization changed in step with thymosin-beta4 expression level.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedTumor cell motility, cell shape and F-actin organization
    Study

    mousen: not reported in source

    Mouse fibrosarcoma cells with graded Tb4 expression
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    We observed that tumor cell motility, cell shape, and F-actin organization is regulated in proportion to the level of thymosin-beta4 expression.
    1 context sentence
    Summary · context
    We identified a thymosin-beta4 gene overexpression in malignant mouse fibrosarcoma cells (QRsP-30) that were derived from clonal weakly tumorigenic and nonmetastatic QR-32 cells by using a differential display method.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.